Kamal Adawi - Oct 20, 2025 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Financial Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Oct 20, 2025
Transactions value $
$0
Form type
4
Date filed
10/21/2025, 04:08 PM
Previous filing
Mar 6, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Adawi Kamal Chief Financial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO /s/ Cindy Tahl, as Attorney-in-Fact 2025-10-21 0001788393

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Award $0 +75K $0.00 75K Oct 20, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +375K $0.00 375K Oct 20, 2025 Common Stock 375K $1.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
F2 The option shall vest as to 25% of the underlying shares on October 20, 2026 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.